98 related articles for article (PubMed ID: 12074403)
1. PSA-use in a Spanish industrial area.
Páez A; Luján M; Llanes L; Romero I; de la Cal MA; Miravalles E; Berenguer A
Eur Urol; 2002 Feb; 41(2):162-6. PubMed ID: 12074403
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the use of prostate specific antigen (PSA) in a health area of the Community of Madrid].
Páez Borda A; Luján Galán M; Llanes González L; Romero Cagigal I; de la Cal López MA; Miravalles González E; Berenguer Sánchez A
Actas Urol Esp; 2001; 25(10):698-703. PubMed ID: 11803775
[TBL] [Abstract][Full Text] [Related]
4. Baseline PSA in a Spanish male population aged 40-49 years anticipates detection of prostate cancer.
Angulo JC; Viñas MA; Gimbernat H; Fata FR; Granados R; Luján M
Actas Urol Esp; 2015 Dec; 39(10):605-11. PubMed ID: 26099906
[TBL] [Abstract][Full Text] [Related]
5. Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Luján M; Páez Á; Angulo JC; Granados R; Nevado M; Torres GM; Berenguer A
Actas Urol Esp; 2016 Apr; 40(3):164-72. PubMed ID: 26620123
[TBL] [Abstract][Full Text] [Related]
6. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
8. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
[TBL] [Abstract][Full Text] [Related]
9. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL.
Babaian RJ; Fritsche H; Ayala A; Bhadkamkar V; Johnston DA; Naccarato W; Zhang Z
Urology; 2000 Dec; 56(6):1000-6. PubMed ID: 11113747
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
[TBL] [Abstract][Full Text] [Related]
11. [Attitude of primary care physicians to early detection of prostatic cancer through prostate-specific antigen].
Oller Colom M; Jiménez Navarrete S; Hidalgo García A; Calvo Rosa E; Pérez Herrera MM; Castellanos Duarte RM; Simón Muela CI; Asens Mampel N; Duaso Allué I; Gascón Gazulla S
Aten Primaria; 2000 Sep; 26(5):323-6. PubMed ID: 11100603
[TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.
Bunting PS; Chong N; Holowaty EJ; Goel V
Clin Biochem; 1998 Aug; 31(6):501-11. PubMed ID: 9740973
[TBL] [Abstract][Full Text] [Related]
14. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
15. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
16. The Finnish prostate cancer screening trial: analyses on the screening failures.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
[TBL] [Abstract][Full Text] [Related]
17. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
18. A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies.
Nordström T; Bratt O; Örtegren J; Aly M; Adolfsson J; Grönberg H
Scand J Urol; 2016; 50(2):104-9. PubMed ID: 26625178
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
20. Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia.
Dantanarayana ND; Hossack T; Cozzi P; Brooks A; Lau H; Delprado W; Patel MI
BMC Urol; 2015 Dec; 15():124. PubMed ID: 26715039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
